Affimed N.V (AFMD)

Etorro trading 970x250
Affimed N.V (AFMD) Logo

About Affimed N.V

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. and Roche. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson’s NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. Address: Technologiepark, Heidelberg, Germany, 69120

Affimed N.V News and around…

Latest news about Affimed N.V (AFMD) common stock and company :

Hedge Funds Have Never Been This Bullish On Affimed NV (AFMD)
25 Oct, 2021 Yahoo! Finance

Is Affimed NV (NASDAQ:AFMD) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]

Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2021
21 Oct, 2021 FinancialContent

Upgrades For Coterra Energy Inc (NYSE:CTRA), Piper Sandler upgraded the previous rating of Neutral to Overweight. The current stock ...

2 Biotech Stocks Set to Go Supernova Soon
18 Oct, 2021 FinancialContent

Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.

10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital
14 Oct, 2021 Yahoo! Finance

In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. If you want to skip our detailed analysis of Stonepine Capital’s history, investment philosophy, and hedge fund preference, go directly to 5 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital. Timothy Lynch is […]

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
01 Oct, 2021 Yahoo! Finance

HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021. Abstract details: Title: Tetravalent, bispecific in

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

New Strong Sell Stocks for September 29th
29 Sep, 2021 Yahoo! Finance

AFMD, FSLR, MU, BCE, and USNA have been added to the Zacks Rank #5 (Strong Sell) List on September 29, 2021.

Peek Under The Hood: OMFS Has 21% Upside
29 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.67 per unit.

New Strong Sell Stocks for September 13th
13 Sep, 2021 Yahoo! Finance

AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.

Affimed NV (NasdaqGM:AFMD) (AFMD) Q2 2021 Earnings Call Transcript
08 Sep, 2021 FinancialContent

AFMD earnings call for the period ending June 30, 2021.

Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
08 Sep, 2021 Yahoo! Finance

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -171.43% and -13.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Stock Market News For Today September 8, 2021
08 Sep, 2021 FinancialContent
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
08 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
08 Sep, 2021 FinancialContent
Earnings Scheduled For September 8, 2021
08 Sep, 2021 FinancialContent

Companies Reporting Before The Bell • Nanobiotix (NASDAQ:NBTX) is likely to report earnings for its first ...

The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
05 Sep, 2021 FinancialContent

Biotech stocks extended their gains in the week endingSept. 3, partly aided by the broader market strength. The news flow was ...

Affimed to Present at Upcoming Investor Conferences
26 Aug, 2021 FinancialContent
Analysts Forecast 19% Upside For OMFS
25 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $47.39 per unit.

Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021
23 Aug, 2021 FinancialContent
Imagine Holding Affimed (NASDAQ:AFMD) Shares While The Price Zoomed 323% Higher
07 Aug, 2021 Yahoo! Finance

The last three months have been tough on Affimed N.V. ( NASDAQ:AFMD ) shareholders, who have seen the share price...

Will Affimed N.V. (AFMD) Report Negative Q2 Earnings? What You Should Know
03 Aug, 2021 Yahoo! Finance

Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors
30 Jul, 2021 FinancialContent
15 Stocks that Will Double In 2021
29 Jul, 2021 Yahoo! Finance

In this article, we discuss the 15 stocks that will double in 2021. If you want to skip our detailed analysis of these stocks, go directly to the 5 Stocks that Will Double In 2021. The economy of 2020 was closely linked to the COVID-19 pandemic. However, the vaccine rollout at the turn of the […]

3 Biotech Stocks That Could Rocket Higher
24 Jul, 2021 FinancialContent

Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.

3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120%
23 Jul, 2021 FinancialContent
3 Biotech Stocks That Could Double Soon
21 Jul, 2021 FinancialContent

Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.

Hedge Funds Are Crazy About Affimed NV (AFMD)
19 Jul, 2021 Yahoo! Finance

A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

Affimed Breaks Below 200-Day Moving Average - Notable for AFMD
14 Jul, 2021 FinancialContent

In trading on Wednesday, shares of Affimed N. .

Analyzing Affimed's Unusual Options Activity
13 Jul, 2021 FinancialContent

Shares of Affimed (NASDAQ:AFMD) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved ...

Affimed Becomes Oversold (AFMD)
06 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Affimed N.V (AFMD) is a NASDAQ Common Stock listed in , ,

970x250